Pricing Log in Create free account
Saturday 17 October 2026 Export UPC’s income statement to Excel — free account

Universe Pharmaceuticals INC

UPC Healthcare Drug Manufacturers Specialty & Generic

Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.

3.97 0.18 −4.34%
Market cap
$20.9M
P/E
0.0×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
0.63
Beneish M
−2.56
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 97.52%

Capital & Financial Ratios $m

Market Cap 20.85
Revenue 82.30
Net Income (17.24)
Free Cash Flow (17.21)
Net Debt (19.50)
Current Ratio 4.05 (at or above 1.5: strong)
Debt/Equity 0.17 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 4.14
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (16.43%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.2×, against a ten-year median of −0.2×; over the ten years it ranged from −0.5× in 2025 to 0.0× in 2023.
EV/FCF against its own 10 years 25.91%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 5 29 34 29
Receivables 13 19 15 22
Inventory 3 2 2 2
Other 4 1 2 2
25 52 54 55
2023 2024 2025 Q'26
Payables 5 5 2 4
ST’ Debt 5 6 9 7
Other — — 0 0
14 20 13 14

Compound Annual Growth %

10y 5y 3y
Sales — (10.27%) (23.66%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 21.96% 6.52%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 18
’24 — — — — 23
’23 — — — — 32
’22 — — — — 40
’21 — — — — 48
’20 — — — — 31
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (5)
’24 — — — — (10)
’23 — — — — 1
’22 — — — — (1)
’21 — — — — (2)
’20 — — — — 6
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) — — — —
’25 2 — (5) — (5)
’24 (2) — (10) — (10)
’23 5 — 1 — 1
’22 6 — (1) — (1)
’21 1 — (13) — (13)
’20 — — 6 — 6
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (8.06)
’24 — — — — (626.96)
’23 — — — — (1.02k)
’22 — — — — (1.44k)
’21 — — — — 2.16k
’20 — — — — 1.70k
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 5,220.00 1,800.00 450.00 24.12 2.51

Analyst estimates 2026–2028

Powerpack
High — — — — — 43,164.00 6,768.00 7,488.00 2,592.00 27.16
People
People Employees — — — — 169 263 224 225 225 216
Revenue/emp, $m — — 0.00 0.00 0.18 0.18 0.18 0.14 0.10 0.08
Income, $m
Income, $m Revenue — — 33 33 31 48 40 32 23 18
Gross margin, % — — 40.35 40.35 45.90 52.78 54.53 31.93 26.37 35.28
EBT — — 10 (3) 10 14 (8) (4) (8) (4)
EBT margin, % — — 29.05 0.00 32.90 28.51 (19.89) (13.39) (35.27) (20.56)
Net income — 0 0 0 8 11 (9) (7) (9) (4)
Depreciation — — 0 0 0 0 1 1 0 1
Per share, $
Per share, $ Revenue — — 0.00 7,552.11 6,978.18 9,053.21 6,690.53 5,384.78 1,656.44 39.17
Earnings — — 2.07 1,697.89 1,699.41 2,158.49 (1,438.99) (1,019.49) (626.96) (8.06)
Cash flow — — 1.21 3,000.86 1,389.82 (387.89) (218.72) 186.13 (683.94) (11.08)
Capex — — 0.00 (19.55) (11.77) (2,089.36) (15.53) (7.37) (25.99) (0.75)
Free cash flow — — 1.21 2,981.32 1,378.05 (2,477.25) (234.25) 178.77 (709.93) (11.83)
Book value — — 0.00 2,814.57 4,727.93 11,119.70 7,740.38 4,661.70 3,273.59 123.12
Shares, m — — 4 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — 4.66 4.66 4.66 2,864.79 2,864.79 0.00 0.00 0.00
P/S — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales — — 0.00 0.00 0.00 0.00 (0.17) 0.00 (0.26) (0.27)
EV/FCF — — 0.00 0.00 0.00 (0.95) 2.00 0.02 3.37 1.47
Cash, $m
Cash, $m Operating cash flow — — 4 13 6 (2) (1) 1 (10) (5)
Capex — — 0 0 0 (11) 0 0 0 0
Free cash flow — — 4 13 6 (13) (1) 1 (10) (5)
Balance, $m
Balance, $m Working capital — — 7 11 15 39 28 12 31 40
Total debt — — 3 3 3 4 4 5 8 9
Net debt — — (3) (1) (7) (17) (15) 0 (22) (24)
Shareholders’ equity — — 12 12 21 59 46 28 46 56
Returns, %
Returns, % ROA — — 42.34 52.65 38.10 22.88 (13.47) (13.00) (15.91) (5.35)
ROIC — — 70.41 0.00 47.85 20.48 (14.75) (8.80) (20.89) (5.73)
ROE — — 122.18 0.00 45.55 28.39 (16.58) (17.69) (23.76) (7.23)
Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jan 0001

Charts ten years each

Universe Pharmaceuticals INC vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IXHL Incannex Healthcare Inc. $36.1M — (loss-making) — (loss-making) −92.31% (below 0%: shrinking) n/m +327.73% (above 0%: growing) 100.00% 0.00% Compare
RMTI Rockwell Medical, Inc. $32.2M — (loss-making) — (loss-making) +10.63% (above 0%: growing) n/m −12.92% (below 0%: shrinking) 18.24% (5.97%) Compare
CPHI China Pharma Holdings, Inc. $31.3M — (loss-making) — (loss-making) −7.56% (below 0%: shrinking) n/m −113.57% (below 0%: shrinking) 8.82% (150.99%) Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc. $26.5M 0.2× — — n/m +82.01% (above 0%: growing) 0.00% 0.00% Compare
TXMD TherapeuticsMD, Inc. $22.3M — (loss-making) 18.9× −8.72% (below 0%: shrinking) −80.00% (below 0%: shrinking) +104.46% (above 0%: growing) 100.00% (93.90%) Compare
AYTU Aytu BioPharma, Inc. $21.8M — (loss-making) — (loss-making) +6.42% (above 0%: growing) n/m +57.72% (above 0%: growing) 64.63% (4.82%) Compare
UPC Universe Pharmaceuticals INC $20.9M — (loss-making) 4.1× −23.98% (below 0%: shrinking) −110.15% (below 0%: shrinking) −84.99% (below 0%: shrinking) 32.57% 0.00%
BGXXQ Bright Green Corporation $13.9M — (loss-making) — — n/m −1.46% (below 0%: shrinking) 0.00% 0.00% Compare
BFRI Biofrontera Inc. $12.6M — (loss-making) — (loss-making) +32.92% (above 0%: growing) n/m +45.57% (above 0%: growing) 79.92% (4.37%) Compare
Median of peers $24.4M — — −0.57% — +51.65% 41.44% (4.60%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Universe Pharmaceuticals INC (UPC) key facts

  • Concern: Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
  • Universe Pharmaceuticals INC (UPC) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, UPC traded at $3.97, a market capitalization of $20.9 million.
  • Return on equity was −7.23% and debt-to-equity 0.17.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.63 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Universe Pharmaceuticals INC (UPC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/UPC · Data as of Jan 3, 0001 · For information only; not investment advice. · © 2026 stockrow.com